CN110200913B - Preparation method of embedded sulbactam amoxicillin amide compound - Google Patents
Preparation method of embedded sulbactam amoxicillin amide compound Download PDFInfo
- Publication number
- CN110200913B CN110200913B CN201910581882.8A CN201910581882A CN110200913B CN 110200913 B CN110200913 B CN 110200913B CN 201910581882 A CN201910581882 A CN 201910581882A CN 110200913 B CN110200913 B CN 110200913B
- Authority
- CN
- China
- Prior art keywords
- sulbactam
- amoxicillin
- water
- embedded
- complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960003022 amoxicillin Drugs 0.000 title claims abstract description 42
- 229960005256 sulbactam Drugs 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 title claims description 21
- -1 sulbactam amoxicillin amide compound Chemical class 0.000 title claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 64
- 238000000265 homogenisation Methods 0.000 claims abstract description 35
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 claims abstract description 30
- 108010000912 Egg Proteins Proteins 0.000 claims abstract description 30
- 102000002322 Egg Proteins Human genes 0.000 claims abstract description 30
- 235000014103 egg white Nutrition 0.000 claims abstract description 30
- 210000000969 egg white Anatomy 0.000 claims abstract description 30
- 239000003921 oil Substances 0.000 claims abstract description 30
- 235000019198 oils Nutrition 0.000 claims abstract description 30
- 241000272525 Anas platyrhynchos Species 0.000 claims abstract description 28
- 239000007908 nanoemulsion Substances 0.000 claims abstract description 21
- 235000012424 soybean oil Nutrition 0.000 claims abstract description 14
- 239000003549 soybean oil Substances 0.000 claims abstract description 14
- 229920001503 Glucan Polymers 0.000 claims abstract description 9
- 238000006243 chemical reaction Methods 0.000 claims description 24
- 238000003756 stirring Methods 0.000 claims description 13
- 239000006228 supernatant Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 8
- 239000011259 mixed solution Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims 2
- 238000001816 cooling Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 15
- 229940079593 drug Drugs 0.000 abstract description 14
- 102000004169 proteins and genes Human genes 0.000 abstract description 14
- 108090000623 proteins and genes Proteins 0.000 abstract description 14
- 239000002245 particle Substances 0.000 abstract description 11
- 230000002776 aggregation Effects 0.000 abstract description 9
- FKENQMMABCRJMK-RITPCOANSA-N sulbactam Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)N2C(=O)C[C@H]21 FKENQMMABCRJMK-RITPCOANSA-N 0.000 abstract description 6
- 238000004220 aggregation Methods 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 5
- 238000005054 agglomeration Methods 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 235000013601 eggs Nutrition 0.000 abstract description 3
- 238000009776 industrial production Methods 0.000 abstract description 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- 229920002307 Dextran Polymers 0.000 description 34
- 239000000203 mixture Substances 0.000 description 12
- 238000000502 dialysis Methods 0.000 description 11
- 239000012153 distilled water Substances 0.000 description 9
- 239000008055 phosphate buffer solution Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 8
- 239000000839 emulsion Substances 0.000 description 8
- 150000003952 β-lactams Chemical class 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000009471 action Effects 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 108010026206 Conalbumin Proteins 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- 108010064983 Ovomucin Proteins 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 229940092253 ovalbumin Drugs 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 241000589291 Acinetobacter Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108020004256 Beta-lactamase Proteins 0.000 description 1
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 208000034892 Typhoid carrier Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229940059260 amidate Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003781 beta lactamase inhibitor Substances 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 229940126813 beta-lactamase inhibitor Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 1
- 229960003324 clavulanic acid Drugs 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- NPUKDXXFDDZOKR-LLVKDONJSA-N etomidate Chemical compound CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 NPUKDXXFDDZOKR-LLVKDONJSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229960003284 iron Drugs 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229940127249 oral antibiotic Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 206010039447 salmonellosis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940126085 β‑Lactamase Inhibitor Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Botany (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种包埋舒巴坦阿莫西林酰胺复合物的制备方法,首先在水中将鸭蛋清中蛋白复合物与葡聚糖共价反应得到接枝物,即水相;再将舒巴坦阿莫西林酰胺复合物溶解大豆油中获得油相;然后通过高压均质将水相和油相混合制得包埋的舒巴坦阿莫西林酰胺复合物药物的纳米乳液。该纳米乳液具有稳定的油水界面膜,水溶性好,为上述复合物的制剂生产带来了可能性;包埋效果好,在12月内无团聚或聚集现象,颗粒均一稳定,且粒径较小,能够较好的被人体吸收。原料简单易得,安全,成本低,制备工艺简单,易于在工业化生产中应用,为非水溶性药品制剂的生产提供了新思路,同时也能促进蛋品产业高附加值成分的综合开发利用,提高经济价值。The invention discloses a preparation method for embedding sulbactam amoxicillinamide complex. First, the protein complex in duck egg white is covalently reacted with glucan in water to obtain a graft, that is, the water phase; The bactam-amoxicillin amide complex is dissolved in soybean oil to obtain an oil phase; and then the water phase and the oil phase are mixed by high-pressure homogenization to prepare a nanoemulsion of the embedded sulbactam-amoxicillin amide complex drug. The nanoemulsion has a stable oil-water interface film and good water solubility, which brings possibilities for the preparation of the above-mentioned complexes; the embedding effect is good, there is no agglomeration or aggregation within 12 months, the particles are uniform and stable, and the particle size is relatively small. Small, can be better absorbed by the body. The raw materials are simple and easy to obtain, safe, low in cost, simple in preparation process, and easy to apply in industrial production, which provides a new idea for the production of water-insoluble pharmaceutical preparations, and can also promote the comprehensive development and utilization of high value-added components in the egg industry, and improve the Economic Value.
Description
技术领域technical field
本发明涉及医药技术领域,特别的涉及一种包埋舒巴坦阿莫西林酰胺复合物的制备方法。The invention relates to the technical field of medicine, in particular to a preparation method of an embedded sulbactam-amoxicillinamide compound.
背景技术Background technique
舒巴坦为人工合成的不可逆的竞争性β-内酰胺酶抑制剂,本身的抗菌活性弱,略强于克拉维酸,单用时仅对淋球菌和不动杆菌属有杀菌作用,它对革兰氏阳性菌和革兰氏阴性菌生产的绝大多数β-内酰胺酶有强大的抑制作用。阿莫西林抗菌谱广、杀菌力强、作用迅速,因其可口服给药而广泛用于临床;可用于治疗伤寒,其他沙门菌感染,伤寒带菌者,尿道、耳、鼻、喉、呼吸道及软组织的感染。WHO推荐其作为首选β-内酰胺类口服抗生素,已成为抗生素品种中最引人注目、发展最快的品种之一。但由于阿莫西林分子中β-内酰胺结构易开环不稳定,易发生降解,且水溶性差,其注射剂中多用其钠盐。舒巴坦也存在一定不稳定性问题,受pH、温度、氧化等因素影响,其β-内酰胺结构也易开环,导致整个分子被破坏,含量下降,有关物增加。Sulbactam is a synthetic and irreversible competitive β-lactamase inhibitor. Its antibacterial activity is weak, slightly stronger than that of clavulanic acid. When used alone, it only has bactericidal effect on Neisseria gonorrhoeae and Acinetobacter. Most β-lactamases produced by blue-positive and gram-negative bacteria have strong inhibitory effects. Amoxicillin has a broad antibacterial spectrum, strong bactericidal power and rapid action. It is widely used in clinical practice because of its oral administration. It can be used to treat typhoid fever, other Salmonella infections, typhoid carriers, urethra, ears, nose, throat, respiratory tract and other diseases. Infection of soft tissue. WHO recommends it as the first-choice β-lactam oral antibiotic, and it has become one of the most eye-catching and fastest-growing antibiotic varieties. However, because the β-lactam structure in the amoxicillin molecule is prone to ring-opening, unstable, prone to degradation, and has poor water solubility, its sodium salt is often used in its injections. Sulbactam also has a certain instability problem. Affected by pH, temperature, oxidation and other factors, its β-lactam structure is also easy to open the ring, resulting in the destruction of the entire molecule, the decrease in content, and the increase in related substances.
在有机药物的化学结构修饰中,成盐、成酯和酰胺的修饰是一类比较常见的方法。利用具有协同性功能的两种不同药物分子,通过使用这些方法修饰后,将两种药物的结构拼合在一个分子内,或将两者的药效基团兼容在一个分子中,是目前药物工作者研究兴趣之一。本发明人在前期研究中(CN201210290947.1),利用修饰技术将阿莫西林和舒巴坦酯通过酰胺化形成舒巴坦阿莫西林酰胺复合物,实现了一种新型结构的舒巴坦阿莫西林酰胺复合物的合成,其结构式如下:In the chemical structure modification of organic drugs, the modification of salt, ester and amide is a kind of common methods. Using two different drug molecules with synergistic functions, after these methods are modified, the structures of the two drugs can be assembled into one molecule, or the pharmacophore of the two can be compatible in one molecule. one of the research interests. In the previous research (CN201210290947.1), the inventors used modification technology to amidate amoxicillin and sulbactam to form sulbactam amoxicillin amide complex, and realized a novel structure of sulbactam The synthesis of moxilinamide complex, its structural formula is as follows:
该酰胺复合物结构上的改造修饰后药物在某种程度上,可以强化药理作用,减小各自相应的毒副作用;或使两者取长补短,发挥各自的药理活性,协同地完成治疗过程;且修饰后更便于拓展临床使用和疾病的治疗与控制。但是,舒巴坦阿莫西林酰胺复合物的水溶解性较低,给制剂生产带来许多不便,限制了其制剂类型特别是水溶液制剂的发展,同时该酰胺复合物仍属β-内酰胺结构,制剂中如何提高其稳定性,也是急需解决的重要问题。 The modified drug on the structure of the amide complex can, to a certain extent, strengthen the pharmacological action and reduce their respective toxic and side effects; Later, it is more convenient to expand clinical use and disease treatment and control. However, the water solubility of the sulbactam-amoxicillin amide complex is low, which brings a lot of inconvenience to the production of preparations, which limits the development of its preparation types, especially the development of aqueous preparations. At the same time, the amide complex is still a β-lactam structure. , how to improve its stability in preparations is also an important problem that needs to be solved urgently.
发明内容SUMMARY OF THE INVENTION
针对上述现有技术的不足,本发明的目的在于提供了一种包埋舒巴坦阿莫西林酰胺复合物的制备方法,解决了舒巴坦阿莫西林酰胺复合物的水溶性差,难以制备水溶性制剂,以及该复合物结构中β-内酰胺结构稳定性差的问题。In view of the above-mentioned deficiencies of the prior art, the purpose of the present invention is to provide a preparation method for embedding the sulbactam amoxicillin amide compound, which solves the problem of the poor water solubility of the sulbactam amoxicillin amide compound, and it is difficult to prepare a water-soluble compound. Sexual preparations, and the problem of poor structural stability of β-lactam in the complex structure.
为了解决上述技术问题,本发明采用了如下的技术方案:一种包埋舒巴坦阿莫西林酰胺复合物的制备方法,包括以下步骤:In order to solve the above-mentioned technical problems, the present invention adopts the following technical scheme: a preparation method for embedding sulbactam amoxicillin amide compound, comprising the following steps:
1)将鸭蛋清溶于水中,然后加入葡聚糖得到混合溶液,再将所述混合溶液的pH调至4~8,室温搅拌1~2h至完全溶解,并将其置于50℃水浴中反应1~6h,反应结束后冷却至室温,离心取上清液,再经透析得到接枝物,即水相;1) Dissolve duck egg white in water, then add dextran to obtain a mixed solution, then adjust the pH of the mixed solution to 4-8, stir at room temperature for 1-2 hours to completely dissolve, and place it in a 50°C water bath The reaction is carried out for 1 to 6 hours, cooled to room temperature after the reaction, centrifuged to take the supernatant, and then dialyzed to obtain the graft, that is, the water phase;
2)将舒巴坦阿莫西林酰胺复合物溶解于大豆油中充分搅拌,得到油相;2) dissolving the sulbactam amoxicillin amide compound in soybean oil and fully stirring to obtain an oil phase;
3)将步骤1)得到的水相和步骤2)得到的油相混合,通过高压均质得到包埋舒巴坦阿莫西林酰胺复合物的纳米乳液。3) Mix the water phase obtained in step 1) and the oil phase obtained in step 2), and obtain a nanoemulsion embedding the sulbactam-amoxicillinamide complex by high-pressure homogenization.
鸭蛋清呈透明胶状,主要包含蛋白质、脂肪、碳水化物、钙、磷、铁、核黄素、尼克酸、维生素A及C等成分。其中,固形物所占比重13%,固形物中大约90%是蛋白质,并以卵白蛋白为主(75%),卵白蛋白多以亲水性蛋白的形式存在,大多数疏水性氨基酸处于分子内部,在高压均质和钙、磷、铁等基团作用下结构极易展开,与卵类粘蛋白(15%)、卵粘蛋白(7%)和伴白蛋白(3%)之间相互作用的蛋白复合物,从而赋予其分子间更强的疏水相互作用和二硫键交联,具有快速的吸附到界面的能力、在达到界面后可迅速伸展和取向以及达到界面后,即与邻近分子相互作用形成具有强内聚力和黏弹性的膜,形成了特定类别的蛋白质类表面活性剂;并且上述蛋白复合物与蛋清中卵转铁蛋白和溶菌酶的协同作用下,进一步提高了其乳化效果。鸭蛋清的成分在蛋白质类型、微量元素和其它的营养素等与其它蛋清存在差异,这些成分上的差异可能导致鸭蛋清适合用于包埋舒巴坦阿莫西林酰胺复合物药物。Duck egg white is transparent and gelatinous, and mainly contains protein, fat, carbohydrate, calcium, phosphorus, iron, riboflavin, niacin, vitamin A and C and other ingredients. Among them, the proportion of solid matter is 13%, and about 90% of the solid matter is protein, mainly ovalbumin (75%), ovalbumin mostly exists in the form of hydrophilic protein, and most of the hydrophobic amino acids are inside the molecule. , the structure is easily unfolded under the action of high pressure homogenization and calcium, phosphorus, iron and other groups, and interacts with ovomucoid (15%), ovomucoid (7%) and conalbumin (3%) protein complexes, thus endow them with stronger hydrophobic interactions and disulfide bond cross-links between molecules, with the ability to rapidly adsorb to the interface, to stretch and orient rapidly after reaching the interface, and to interact with neighboring molecules after reaching the interface. The interaction forms a film with strong cohesion and viscoelasticity, forming a specific type of protein surfactant; and the synergistic effect of the above protein complex with ovotransferrin and lysozyme in egg white further improves its emulsification effect. The composition of duck egg white is different from other egg whites in terms of protein type, trace elements and other nutrients. These differences in composition may make duck egg white suitable for encapsulating sulbactam-amoxicillinamide compound drugs.
在高压下所产生的强烈剪切、撞击和空穴作用,蛋清形成具有蛋白质类表面活性剂的蛋白复合物,该蛋白复合物的亲水基团和水相结合,亲油基团和油相结合,这样复合蛋白会束缚在乳滴表面形成油水界面膜,从而获得油滴固定并完成舒巴坦阿莫西林酰胺复合物药物的高效负载和包埋,形成了无数个微小甚至达到了微米或纳米级的乳液。通过利用空化效应产生的微射流,使油相和水相混和均匀,使液态物质得到超细微化。同时接枝连接在蛋清蛋白上的葡聚糖由于其亲水性而在乳滴表面伸展,使乳滴在水中长时间稳定存在,避免其沉淀和聚集。Under the strong shearing, impacting and cavitation generated under high pressure, egg white forms a protein complex with protein-like surfactants, the hydrophilic group of the protein complex is combined with water, and the lipophilic group and oil phase Combined, the complex protein will be bound on the surface of the emulsion droplets to form an oil-water interface film, so as to obtain the immobilization of the oil droplets and complete the efficient loading and entrapment of the sulbactam-amoxicillinamide complex drug, forming countless microscopic or even micron or Nanoscale emulsion. The oil phase and the water phase are uniformly mixed by using the micro-jet generated by the cavitation effect, so that the liquid substance is ultra-fine. At the same time, the glucan grafted on the egg white protein stretches on the surface of the milk droplets due to its hydrophilicity, so that the milk droplets can exist stably in the water for a long time and avoid their precipitation and aggregation.
作为优选的,所述鸭蛋清、水和葡聚糖的质量为1:2~10:0.05~0.2。Preferably, the mass of the duck egg white, water and glucan is 1:2-10:0.05-0.2.
作为优选的,所述葡聚糖的分子量在5000~50000。Preferably, the molecular weight of the glucan is 5000-50000.
作为优选的,步骤2)所述舒巴坦阿莫西林酰胺复合物溶解于大豆油中的浓度为5~100mg/ml。Preferably, the concentration of the sulbactam-amoxicillinamide compound dissolved in soybean oil in step 2) is 5-100 mg/ml.
作为优选的,所述水相和油相的混合体积比为1:5~20。Preferably, the mixing volume ratio of the water phase and the oil phase is 1:5-20.
作为优选的,所述高压均质的压力范围为300~500bar,高压均质时间范围为10~30min。Preferably, the pressure range of the high-pressure homogenization is 300-500 bar, and the high-pressure homogenization time range is 10-30 min.
作为优选的,所述离心速度为4000~6000rpm,离心时间为10~20min。Preferably, the centrifugal speed is 4000-6000 rpm, and the centrifugal time is 10-20 min.
作为优选的,所述透析中透析膜的分子量为10±0.2kDa。Preferably, the molecular weight of the dialysis membrane in the dialysis is 10±0.2kDa.
相比现有技术,本发明具有如下有益效果:Compared with the prior art, the present invention has the following beneficial effects:
1、本发明所提供舒巴坦阿莫西林酰胺复合物药物-蛋白复合物-葡聚糖包埋型的纳米乳液是一种以包含舒巴坦阿莫西林酰胺复合物药物的油相为内核,鸭蛋清中蛋白复合物为油水界面膜,蛋白复合物上接枝的葡聚糖处于纳米乳液外层。该纳米乳液具有稳定的油水界面膜,由于葡聚糖亲水性而在乳滴表面伸展,避免乳滴聚集,其水溶性好,为上述复合物的制剂生产带来了可能性;包埋效果好,提高复合物的稳定性,在12月内无团聚或聚集现象,提高了舒巴坦阿莫西林酰胺复合物药物的有效贮存期,具有良好的应用前景。1. The sulbactam amoxicillin amide complex drug-protein complex-dextran-embedded nanoemulsion provided by the present invention is a kind of oil phase containing the sulbactam amoxicillin amide complex drug as the core. , the protein complex in duck egg white is an oil-water interface film, and the dextran grafted on the protein complex is in the outer layer of the nanoemulsion. The nanoemulsion has a stable oil-water interface film, which is stretched on the surface of emulsion droplets due to the hydrophilicity of dextran to avoid the aggregation of emulsion droplets. Well, the stability of the complex is improved, there is no agglomeration or aggregation phenomenon within 12 months, the effective storage period of the sulbactam-amoxicillinamide complex drug is improved, and the drug has a good application prospect.
2、本发明制备的纳米乳液颗粒均一稳定,且粒径较小,能够较好的被人体吸收。使用时在人体消化酶的作用下随着葡聚糖和蛋白质的降解而释放出舒巴坦阿莫西林酰胺复合物药物,发挥相应功效;同时分解得到的葡萄糖和蛋白肽也为人体提供了营养物质。2. The nanoemulsion particles prepared by the present invention are uniform and stable, and the particle size is small, which can be better absorbed by the human body. When in use, under the action of human digestive enzymes, sulbactam amoxicillinamide compound drug is released along with the degradation of glucan and protein to exert corresponding effects; at the same time, the decomposed glucose and protein peptides also provide nutrition for the human body substance.
3、本发明以葡聚糖和鸭蛋清为原料,属常规食品,无毒易降解,安全,成本低,制备工艺简单,生产周期短,易于在工业化生产中应用,也为非水溶性药品制剂的生产提供了新思路,同时也能促进蛋品产业高附加值成分的综合开发利用,提高经济价值。3. The present invention uses glucan and duck egg white as raw materials, belongs to conventional food, is non-toxic and easy to degrade, is safe, low in cost, simple in preparation process, short in production cycle, easy to be applied in industrial production, and is also a water-insoluble pharmaceutical preparation The production of egg products provides new ideas, and at the same time can promote the comprehensive development and utilization of high value-added components in the egg industry, and improve the economic value.
附图说明Description of drawings
图1为本发明实施例1制备包埋后舒巴坦阿莫西林酰胺复合物药物-蛋白复合物-葡聚糖纳米乳液的纳米颗粒粒径分布图。Fig. 1 is a particle size distribution diagram of nanoparticles of sulbactam-amoxicillinamide complex drug-protein complex-dextran nanoemulsion prepared after embedding in Example 1 of the present invention.
具体实施方式Detailed ways
下面结合实施例对本发明作进一步的详细说明。The present invention will be further described in detail below in conjunction with the examples.
实施例1Example 1
1)在反应瓶中将鸭蛋清溶于2倍体积的蒸馏水中,然后加入分子量为25000的葡聚糖,使葡聚糖的添加量为鸭蛋清质量的0.05倍,再用磷酸盐缓冲溶液调节上述溶液pH到4.0,室温搅拌2h至完全溶解,并将其置于40℃水浴中反应1h,反应结束后冷却至室温,于4000rpm离心15min除去不溶物,取上清液4℃下透析24h(透析分子量10±0.2kDa)后得接枝物,即为水相;1) Dissolve duck egg white in 2 times the volume of distilled water in the reaction flask, then add dextran with a molecular weight of 25,000, so that the amount of dextran added is 0.05 times the mass of duck egg white, and then adjust with phosphate buffer solution The pH of the above solution reached 4.0, stirred at room temperature for 2 hours to completely dissolve, and placed it in a water bath at 40 °C for 1 hour. After the reaction was completed, it was cooled to room temperature, centrifuged at 4000 rpm for 15 minutes to remove insoluble matter, and the supernatant was dialyzed at 4 °C for 24 hours ( After dialysis
2)将舒巴坦阿莫西林酰胺复合物溶解于大豆油中充分搅拌,使舒巴坦阿莫西林酰胺复合物的浓度为5mg/ml,得到油相;2) Dissolving the sulbactam-amoxicillin amide complex in soybean oil and stirring sufficiently to make the concentration of the sulbactam-amoxicillin amide complex be 5 mg/ml to obtain an oil phase;
3)将步骤1)得到的水相和步骤2)得到的油相按照体积比5:1混合,通过高压均质得到所述包埋后的舒巴坦阿莫西林酰胺复合物药物-蛋白复合物-葡聚糖纳米乳液,其中高压均质的压力为500bar,高压均质时间为10min。3) Mix the water phase obtained in step 1) and the oil phase obtained in step 2) according to a volume ratio of 5:1, and obtain the embedded sulbactam-amoxicillinamide complex drug-protein complex by high-pressure homogenization A substance-dextran nanoemulsion, wherein the pressure of high-pressure homogenization is 500bar, and the time of high-pressure homogenization is 10min.
实施例2Example 2
1)在反应瓶中将鸭蛋清溶于10倍体积的蒸馏水中,然后加入分子量为50000的葡聚糖,使葡聚糖的添加量为鸭蛋清质量的0.2倍,再用磷酸盐缓冲溶液调节上述溶液pH到8.0,室温搅拌2h至完全溶解,并将其置于40℃水浴中反应6h,反应结束后冷却至室温,于6000rpm离心10min除去不溶物,取上清液4℃下透析24h(透析分子量10±0.2kDa)后得接枝物,即为水相;1) Dissolve duck egg white in 10 times the volume of distilled water in the reaction flask, then add dextran with a molecular weight of 50,000, so that the amount of dextran added is 0.2 times the mass of duck egg white, and then adjust with phosphate buffer solution The pH of the above solution reached 8.0, stirred at room temperature for 2 hours to completely dissolve, and placed it in a 40 °C water bath for 6 hours. After the reaction was completed, it was cooled to room temperature, centrifuged at 6000 rpm for 10 minutes to remove insoluble matter, and the supernatant was dialyzed at 4 °C for 24 hours ( After dialysis
2)将舒巴坦阿莫西林酰胺复合物溶解于大豆油中充分搅拌,使舒巴坦阿莫西林酰胺复合物的浓度为100mg/ml,得到油相;2) dissolving the sulbactam-amoxicillin amide complex in soybean oil and fully stirring, so that the concentration of the sulbactam-amoxicillin amide complex is 100 mg/ml, to obtain an oil phase;
3)将步骤1)得到的水相和步骤2)得到的油相按照体积比20:1混合,通过高压均质得到所述包埋后的舒巴坦阿莫西林酰胺复合物药物-蛋白复合物-葡聚糖纳米乳液,其中高压均质的压力为400bar,高压均质时间为30min。3) Mix the water phase obtained in step 1) and the oil phase obtained in step 2) according to a volume ratio of 20:1, and obtain the embedded sulbactam-amoxicillinamide compound drug-protein compound by high-pressure homogenization A substance-dextran nanoemulsion, wherein the pressure of high-pressure homogenization is 400bar, and the time of high-pressure homogenization is 30min.
实施例3Example 3
1)在反应瓶中将鸭蛋清溶于5倍体积的蒸馏水中,然后加入分子量为5000的葡聚糖,使葡聚糖的添加量为鸭蛋清质量的0.1倍,再用磷酸盐缓冲溶液调节上述溶液pH到5.0,室温搅拌2h至完全溶解,并将其置于40℃水浴中反应2h,反应结束后冷却至室温,于5000rpm离心20min除去不溶物,取上清液4℃下透析24h(透析分子量10±0.2kDa)后得接枝物,即为水相;1) Dissolve duck egg white in 5 times the volume of distilled water in the reaction flask, then add dextran with a molecular weight of 5000, so that the amount of dextran added is 0.1 times the mass of duck egg white, and then adjust with phosphate buffer solution The pH of the above solution reached 5.0, stirred at room temperature for 2 hours to completely dissolve, and placed it in a 40°C water bath for 2 hours of reaction. After the reaction was completed, it was cooled to room temperature, centrifuged at 5000rpm for 20min to remove insoluble matter, and the supernatant was dialyzed at 4°C for 24h ( After dialysis
2)将舒巴坦阿莫西林酰胺复合物溶解于大豆油中充分搅拌,使舒巴坦阿莫西林酰胺复合物的浓度为50mg/ml,得到油相;2) dissolving the sulbactam-amoxicillin amide complex in soybean oil and fully stirring, so that the concentration of the sulbactam-amoxicillin amide complex is 50 mg/ml, to obtain an oil phase;
3)将步骤1)得到的水相和步骤2)得到的油相按照体积比10:1混合,通过高压均质得到所述包埋后的舒巴坦阿莫西林酰胺复合物药物-蛋白复合物-葡聚糖纳米乳液,其中高压均质的压力为300bar,高压均质时间为20min。3) Mix the water phase obtained in step 1) and the oil phase obtained in step 2) according to a volume ratio of 10:1, and obtain the embedded sulbactam-amoxicillinamide complex drug-protein complex by high-pressure homogenization The compound-dextran nanoemulsion, wherein the pressure of high-pressure homogenization is 300bar, and the time of high-pressure homogenization is 20min.
实施例4Example 4
1)在反应瓶中将鸭蛋清溶于5倍体积的蒸馏水中,然后加入分子量为30000的葡聚糖,使葡聚糖的添加量为鸭蛋清质量的0.15倍,再用磷酸盐缓冲溶液调节上述溶液pH到7.0,室温搅拌2h至完全溶解,并将其置于40℃水浴中反应1h,反应结束后冷却至室温,于4000rpm离心20min除去不溶物,取上清液4℃下透析24h(透析分子量10±0.2kDa)后得接枝物,即为水相;1) Dissolve duck egg white in 5 times the volume of distilled water in the reaction flask, then add dextran with a molecular weight of 30,000, so that the amount of dextran added is 0.15 times the mass of duck egg white, and then adjust with phosphate buffer solution The pH of the above solution reached 7.0, stirred at room temperature for 2 hours to completely dissolve, and placed it in a water bath at 40 °C for 1 hour. After the reaction was completed, it was cooled to room temperature, centrifuged at 4000 rpm for 20 minutes to remove insoluble matter, and the supernatant was dialyzed at 4 °C for 24 hours ( After dialysis
2)将舒巴坦阿莫西林酰胺复合物溶解于大豆油中充分搅拌,使舒巴坦阿莫西林酰胺复合物的浓度为20mg/ml,得到油相;2) Dissolving the sulbactam-amoxicillin amide complex in soybean oil and fully stirring, so that the concentration of the sulbactam-amoxicillin amide complex is 20 mg/ml, to obtain an oil phase;
3)将步骤1)得到的水相和步骤2)得到的油相按照体积比10:1混合,通过高压均质得到所述包埋后的舒巴坦阿莫西林酰胺复合物药物-蛋白复合物-葡聚糖纳米乳液,其中高压均质的压力为400bar,高压均质时间为15min。3) Mix the water phase obtained in step 1) and the oil phase obtained in step 2) according to a volume ratio of 10:1, and obtain the embedded sulbactam-amoxicillinamide complex drug-protein complex by high-pressure homogenization A substance-dextran nanoemulsion, wherein the pressure of high-pressure homogenization is 400bar, and the time of high-pressure homogenization is 15min.
实施例5Example 5
1)在反应瓶中将鸭蛋清溶于5倍体积的蒸馏水中,然后加入分子量为40000的葡聚糖,使葡聚糖的添加量为鸭蛋清质量的0.2倍,再用磷酸盐缓冲溶液调节上述溶液pH到6.0,室温搅拌2h至完全溶解,并将其置于40℃水浴中反应1h,反应结束后冷却至室温,于4000rpm离心15min除去不溶物,取上清液4℃下透析24h(透析分子量10±0.2kDa)后得接枝物,即为水相;1) Dissolve duck egg white in 5 times the volume of distilled water in the reaction flask, then add dextran with a molecular weight of 40,000, so that the amount of dextran added is 0.2 times the mass of duck egg white, and then adjust with phosphate buffer solution The pH of the above solution reached 6.0, stirred at room temperature for 2 hours to completely dissolve, and placed it in a 40°C water bath for 1 hour of reaction. After the reaction was completed, it was cooled to room temperature, centrifuged at 4000 rpm for 15 minutes to remove insoluble matter, and the supernatant was dialyzed at 4°C for 24h ( After dialysis
2)将舒巴坦阿莫西林酰胺复合物溶解于大豆油中充分搅拌,使舒巴坦阿莫西林酰胺复合物的浓度为50mg/ml,得到油相;2) dissolving the sulbactam-amoxicillin amide complex in soybean oil and fully stirring, so that the concentration of the sulbactam-amoxicillin amide complex is 50 mg/ml, to obtain an oil phase;
3)将步骤1)得到的水相和步骤2)得到的油相按照体积比15:1混合,通过高压均质得到所述包埋后的舒巴坦阿莫西林酰胺复合物药物-蛋白复合物-葡聚糖纳米乳液,其中高压均质的压力为500bar,高压均质时间为10min。3) Mix the water phase obtained in step 1) and the oil phase obtained in step 2) according to a volume ratio of 15:1, and obtain the embedded sulbactam-amoxicillinamide complex drug-protein complex by high-pressure homogenization A substance-dextran nanoemulsion, wherein the pressure of high-pressure homogenization is 500bar, and the time of high-pressure homogenization is 10min.
实施例6Example 6
1)在反应瓶中将鸭蛋清溶于10倍体积的蒸馏水中,然后加入分子量为6000的葡聚糖,使葡聚糖的添加量为鸭蛋清质量的0.05倍,再用磷酸盐缓冲溶液调节上述溶液pH到4.0,室温搅拌2h至完全溶解,并将其置于40℃水浴中反应2.5h,反应结束后冷却至室温,于6000rpm离心10min除去不溶物,取上清液4℃下透析24h(透析分子量10±0.2kDa)后得接枝物,即为水相;1) Dissolve duck egg white in 10 times the volume of distilled water in the reaction flask, then add dextran with a molecular weight of 6000, so that the amount of dextran added is 0.05 times the mass of duck egg white, and then adjust with phosphate buffer solution The pH of the above solution reached 4.0, stirred at room temperature for 2 hours to completely dissolve, and placed it in a water bath at 40 °C for 2.5 hours. After the reaction was completed, it was cooled to room temperature, centrifuged at 6000 rpm for 10 minutes to remove insoluble matter, and the supernatant was dialyzed at 4 °C for 24 hours. (The molecular weight of dialysis is 10±0.2kDa) to obtain the graft, which is the water phase;
2)将舒巴坦阿莫西林酰胺复合物溶解于大豆油中充分搅拌,使舒巴坦阿莫西林酰胺复合物的浓度为50mg/ml,得到油相;2) dissolving the sulbactam-amoxicillin amide complex in soybean oil and fully stirring, so that the concentration of the sulbactam-amoxicillin amide complex is 50 mg/ml, to obtain an oil phase;
3)将步骤1)得到的水相和步骤2)得到的油相按照体积比10:1混合,通过高压均质得到所述包埋后的舒巴坦阿莫西林酰胺复合物药物-蛋白复合物-葡聚糖纳米乳液,其中高压均质的压力为300bar,高压均质时间为20min。3) Mix the water phase obtained in step 1) and the oil phase obtained in step 2) according to a volume ratio of 10:1, and obtain the embedded sulbactam-amoxicillinamide complex drug-protein complex by high-pressure homogenization The compound-dextran nanoemulsion, wherein the pressure of high-pressure homogenization is 300bar, and the time of high-pressure homogenization is 20min.
实施例7Example 7
1)在反应瓶中将鸭蛋清溶于2倍体积的蒸馏水中,然后加入分子量为10000的葡聚糖,使葡聚糖的添加量为鸭蛋清质量的0.2倍,再用磷酸盐缓冲溶液调节上述溶液pH到4.0,室温搅拌2h至完全溶解,并将其置于40℃水浴中反应5h,反应结束后冷却至室温,于6000rpm离心20min除去不溶物,取上清液4℃下透析24h(透析分子量10±0.2kDa)后得接枝物,即为水相;1) Dissolve duck egg white in 2 times the volume of distilled water in the reaction flask, then add dextran with a molecular weight of 10,000, so that the amount of dextran added is 0.2 times the mass of duck egg white, and then adjust with phosphate buffer solution The pH of the above solution reached 4.0, stirred at room temperature for 2 hours until completely dissolved, and placed it in a 40 °C water bath for 5 hours. After the reaction was completed, it was cooled to room temperature, centrifuged at 6000 rpm for 20 minutes to remove insoluble matter, and the supernatant was dialyzed at 4 °C for 24 hours ( After dialysis
2)将舒巴坦阿莫西林酰胺复合物溶解于大豆油中充分搅拌,使舒巴坦阿莫西林酰胺复合物的浓度为50mg/ml,得到油相;2) dissolving the sulbactam-amoxicillin amide complex in soybean oil and fully stirring, so that the concentration of the sulbactam-amoxicillin amide complex is 50 mg/ml, to obtain an oil phase;
3)将步骤1)得到的水相和步骤2)得到的油相按照体积比10:1混合,通过高压均质得到所述包埋后的舒巴坦阿莫西林酰胺复合物药物-蛋白复合物-葡聚糖纳米乳液,其中高压均质的压力为300bar,高压均质时间为20min。3) Mix the water phase obtained in step 1) and the oil phase obtained in step 2) according to a volume ratio of 10:1, and obtain the embedded sulbactam-amoxicillinamide complex drug-protein complex by high-pressure homogenization The compound-dextran nanoemulsion, wherein the pressure of high-pressure homogenization is 300bar, and the time of high-pressure homogenization is 20min.
实施例8Example 8
1)在反应瓶中将鸭蛋清溶于5倍体积的蒸馏水中,然后加入分子量为25000的葡聚糖,使葡聚糖的添加量为鸭蛋清质量的0.2倍,再用磷酸盐缓冲溶液调节上述溶液pH到5.0,室温搅拌2h至完全溶解,并将其置于40℃水浴中反应5h,反应结束后冷却至室温,于4000rpm离心20min除去不溶物,取上清液4℃下透析24h(透析分子量10±0.2kDa)后得接枝物,即为水相;1) Dissolve duck egg white in 5 times the volume of distilled water in the reaction flask, then add dextran with a molecular weight of 25,000, so that the amount of dextran added is 0.2 times the mass of duck egg white, and then adjust with phosphate buffer solution The pH of the above solution reached 5.0, stirred at room temperature for 2 hours until completely dissolved, and placed it in a 40 °C water bath for 5 hours. After the reaction was completed, it was cooled to room temperature, centrifuged at 4000 rpm for 20 minutes to remove insoluble matter, and the supernatant was dialyzed at 4 °C for 24 hours ( After dialysis
2)将舒巴坦阿莫西林酰胺复合物溶解于大豆油中充分搅拌,使舒巴坦阿莫西林酰胺复合物的浓度为50mg/ml,得到油相;2) dissolving the sulbactam-amoxicillin amide complex in soybean oil and fully stirring, so that the concentration of the sulbactam-amoxicillin amide complex is 50 mg/ml, to obtain an oil phase;
3)将步骤1)得到的水相和步骤2)得到的油相按照体积比5:1混合,通过高压均质得到所述包埋后的舒巴坦阿莫西林酰胺复合物药物-蛋白复合物-葡聚糖纳米乳液,其中高压均质的压力为300bar,高压均质时间为30min。3) Mix the water phase obtained in step 1) and the oil phase obtained in step 2) according to a volume ratio of 5:1, and obtain the embedded sulbactam-amoxicillinamide complex drug-protein complex by high-pressure homogenization The substance-dextran nanoemulsion, wherein the pressure of high-pressure homogenization is 300bar, and the time of high-pressure homogenization is 30min.
实施例9Example 9
1)在反应瓶中将鸭蛋清溶于2倍体积的蒸馏水中,然后加入分子量为10000的葡聚糖,使葡聚糖的添加量为鸭蛋清质量的0.2倍,再用磷酸盐缓冲溶液调节上述溶液pH到7.0,室温搅拌2h至完全溶解,并将其置于40℃水浴中反应5h,反应结束后冷却至室温,于4000rpm离心15min除去不溶物,取上清液4℃下透析24h(透析分子量10±0.2kDa)后得接枝物,即为水相;1) Dissolve duck egg white in 2 times the volume of distilled water in the reaction flask, then add dextran with a molecular weight of 10,000, so that the amount of dextran added is 0.2 times the mass of duck egg white, and then adjust with phosphate buffer solution The pH of the above solution reached 7.0, stirred at room temperature for 2 hours to completely dissolve, and placed it in a 40 °C water bath for 5 hours. After the reaction was completed, it was cooled to room temperature, centrifuged at 4000 rpm for 15 minutes to remove insoluble matter, and the supernatant was dialyzed at 4 °C for 24 hours ( After dialysis
2)将舒巴坦阿莫西林酰胺复合物溶解于大豆油中充分搅拌,使舒巴坦阿莫西林酰胺复合物的浓度为50mg/ml,得到油相;2) dissolving the sulbactam-amoxicillin amide complex in soybean oil and fully stirring, so that the concentration of the sulbactam-amoxicillin amide complex is 50 mg/ml, to obtain an oil phase;
3)将步骤1)得到的水相和步骤2)得到的油相按照体积比10:1混合,通过高压均质得到所述包埋后的舒巴坦阿莫西林酰胺复合物药物-蛋白复合物-葡聚糖纳米乳液,其中高压均质的压力为500bar,高压均质时间为20min。3) Mix the water phase obtained in step 1) and the oil phase obtained in step 2) according to a volume ratio of 10:1, and obtain the embedded sulbactam-amoxicillinamide complex drug-protein complex by high-pressure homogenization A substance-dextran nanoemulsion, wherein the pressure of high-pressure homogenization is 500bar, and the time of high-pressure homogenization is 20min.
将实施例1制备的舒巴坦阿莫西林酰胺复合物药物-蛋白复合物-葡聚糖纳米水乳液通过激光粒度仪检测乳液粒径,结果如图1。从图中可以看出,本发明制备的舒巴坦阿莫西林酰胺复合物药物-蛋白复合物-葡聚糖纳米水乳液的粒径约为237.7±9.31nm,该乳液可以通过450nm滤膜达到除菌的目的。The sulbactam-amoxicillinamide complex drug-protein complex-dextran nano-aqueous emulsion prepared in Example 1 was tested for the particle size of the emulsion by a laser particle size analyzer, and the results are shown in Figure 1. As can be seen from the figure, the particle size of the sulbactam-amoxicillinamide complex drug-protein complex-dextran nano-water emulsion prepared by the present invention is about 237.7±9.31nm, and the emulsion can be passed through a 450nm filter membrane to achieve purpose of sterilization.
将实施例1~9制备的舒巴坦阿莫西林酰胺复合物药物-蛋白复合物-葡聚糖纳米水乳液在不同时间段对其粒径和载药量进行测定,结果如表1所示。The particle size and drug loading of the sulbactam-amoxicillinamide complex drug-protein complex-dextran nano-emulsion prepared in Examples 1-9 were measured at different time periods, and the results are shown in Table 1. .
表1Table 1
由表1可以看出,在不同时间段内,本发明制备的纳米乳液对舒巴坦阿莫西林酰胺复合物药物的载药量没有显著的变化,说明其具有良好的包埋效果,在12个月内无团聚或聚集现象,说明其具有良好的稳定性;颗粒均一稳定,在水溶液中无团聚现象,说明制备的纳米乳液具有良好的水溶性,且粒径较小,易吸收。As can be seen from Table 1, in different time periods, the nanoemulsion prepared by the present invention has no significant change in the drug loading of the sulbactam-amoxicillinamide compound drug, indicating that it has a good embedding effect. There is no agglomeration or aggregation within a month, indicating that it has good stability; the particles are uniform and stable, and there is no agglomeration in the aqueous solution, indicating that the prepared nanoemulsion has good water solubility, and the particle size is small and easy to absorb.
以上所述仅为本发明的较佳实施例而已,并不以本发明为限制,凡在本发明的精神和原则之内所作的任何修改、等同替换和改进等,均应包含在本发明的保护范围之内。The above descriptions are only preferred embodiments of the present invention, and are not intended to limit the present invention. Any modifications, equivalent replacements and improvements made within the spirit and principles of the present invention shall be included in the scope of the present invention. within the scope of protection.
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910581882.8A CN110200913B (en) | 2019-06-30 | 2019-06-30 | Preparation method of embedded sulbactam amoxicillin amide compound |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910581882.8A CN110200913B (en) | 2019-06-30 | 2019-06-30 | Preparation method of embedded sulbactam amoxicillin amide compound |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110200913A CN110200913A (en) | 2019-09-06 |
CN110200913B true CN110200913B (en) | 2020-11-06 |
Family
ID=67795496
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910581882.8A Active CN110200913B (en) | 2019-06-30 | 2019-06-30 | Preparation method of embedded sulbactam amoxicillin amide compound |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110200913B (en) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08104620A (en) * | 1994-10-05 | 1996-04-23 | Green Cross Corp:The | Drug-containing fat emulsion |
GB0503684D0 (en) * | 2005-02-23 | 2005-03-30 | Ici Plc | Emulsifiers and emulsions |
CN102302450B (en) * | 2011-09-06 | 2013-02-27 | 复旦大学 | Hydrophobic drug-albumin-dextran nanoemulsion and its preparation method and application |
CN102786536B (en) * | 2012-08-16 | 2014-08-20 | 重庆大学 | Sulbactam amoxicillin amide complex for treatment of acute bacterial infection of pig and synthesis method |
-
2019
- 2019-06-30 CN CN201910581882.8A patent/CN110200913B/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN110200913A (en) | 2019-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104434791B (en) | A kind of preparation of modified bletilla polysaccharide derivates nanometer carrier and application technology | |
CN108578357A (en) | A kind of protein-polysaccharide self-assembled nanometer gel and the preparation method and application thereof with nucleocapsid structure | |
CN105054073B (en) | A kind of water miscible vitamine D3 nano particle and preparation method thereof | |
KR20200132584A (en) | Stabilized astaxanthin nanoparticles and its manufacturing method | |
CN104161745A (en) | Method for preparing nanometer iron citrate liposome | |
CN109260177B (en) | A kind of preparation method and application of berberine hydrochloride composite nanoparticles | |
CN105381472B (en) | Oenothera biennis element B- casein phosphopeptide-chitosan nanoparticle and preparation method and application | |
CN114225046A (en) | Antibacterial/healing-promoting dual-drug delivery system, pharmaceutical composition and preparation method and application thereof | |
CN101455645B (en) | Preparation method of medicine microspheres using plant soy protein as carrier | |
CN108096188B (en) | Oil-in-water composite nanoemulsion loaded with hydrophobic drugs and nutrients and preparation method thereof | |
CN113797177B (en) | Quercetin oral sustained-release preparation modified by ionic emulsifier chitosan nanoparticles and preparation method thereof | |
CN102552293B (en) | A kind of compound vitamin submicron emulsion freeze-dried powder for injection and preparation method thereof | |
CN102010513B (en) | Stable polysaccharide modified gelatin nano particle and preparation method and application thereof | |
CN104490933B (en) | Crocodile blood nano microcapsule and preparation method thereof | |
CN110200913B (en) | Preparation method of embedded sulbactam amoxicillin amide compound | |
CN106421807A (en) | A kind of preparation method of insulin-loaded carboxymethyl chitosan/chitosan nano preparation | |
CN115739031A (en) | Application of chitosan or derivatives thereof in removing endotoxin in gelatin | |
CN105126102A (en) | Hypocrellin B nanoparticle and preparation method thereof | |
CN116139294B (en) | L-glutamine-zein-naringenin nanoparticles and applications thereof | |
CN102210655A (en) | Cefpiramide sodium micro-spheres and preparing method thereof | |
CN114432243B (en) | Nanocarrier responding to pH and glucose and application thereof | |
CN114522150B (en) | Preparation method and application of a pH-sensitive plant microcapsule nano-extruder | |
CN117084969A (en) | Injectable hydrogel doped with pearl powder, preparation method and application | |
CN116218831A (en) | Alcohol oxidase stabilized nanoparticles, preparation method, application and hangover drug | |
CN113133987B (en) | Preparation method of ultra-long circulating nano-carrier for tenib drugs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |